Quest for the right Drug

|
עמוד הבית / אדנו-אבניר / מידע מעלון לרופא

אדנו-אבניר ADENO-AVENIR (ADENOSINE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי : I.V

צורת מינון:

תמיסה להזרקה : SOLUTION FOR INJECTION

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Cardiovascular system, cardiac therapy, other cardiac preparations, ATC code: C01EB10
Mechanism of action
Endogenous nucleoside with peripheral vasodilator/antiarrhythmic effect; antiarrhythmic drug.
Adenosine is a purine nucleoside which is present in all cells of the body. Animal pharmacology studies have in several species shown that Adenosine has a negative dromotropic effect on the atrioventricular (AV) node.
In man, Adeno-Avenir (adenosine) administered by rapid intravenous injection slows conduction through the AV node. This action can interrupt re-entry circuits involving the AV node and restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardias. Once the circuit has been interrupted, the tachycardia stops, and normal sinus rhythm is re-established.
One acute interruption of the circuit is usually sufficient to arrest the tachycardia.
Since atrial fibrillation and atrial flutter do not involve the AV node as part of a re-entry circuit, Adenosine will not terminate these arrhythmias.
By transiently slowing AV conduction, atrial activity is easier to evaluate from ECG recordings and therefore the use of Adenosine can aid the diagnosis of broad or narrow complex tachycardias.
Adenosine may be useful during electrophysiological studies to determine the site of AV block or to determine in some cases of pre-excitation, whether conduction is occurring by an accessory pathway or via the AV node.

Pharmacokinetic Properties

5.2 Pharmacokinetic properties
Adenosine is impossible to study via classical ADME protocols. It is present in various forms in all cells of the body where it plays an important role in energy production and utilisation systems. An efficient salvage and recycling system exists in the body, primarily in the erythrocytes and blood vessel endothelial cells. The half-life in vitro is estimated to be < 10 seconds. The in vivo half-life may be even shorter.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/03/2001
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

BIOAVENIR LTD, ISRAEL

רישום

155 15 34258 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

14.04.21 - עלון לרופא 01.02.24 - עלון לרופא

עלון מידע לצרכן

09.02.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אדנו-אבניר

קישורים נוספים

RxList WebMD Drugs.com